Market Flux Event
Merck Scraps Nemtabrutinib Blood Cancer Program After Safety Review of Phase 3 Trials
Read this in the Market Flux appMerck has discontinued its entire BELLWAVE clinical development program for nemtabrutinib (MK-1026), an investigational oral non-covalent Bruton's tyrosine kinase (BTK) inhibitor being evaluated for chronic lymphocytic leukemia, small lymphocytic leukemia, and other hematologic malignancies. The decision was announced November 17, 2026, ending a program that had reached Phase 3 testing.
Three late-stage studies were stopped: BELLWAVE-011 (NCT06136559) was discontinued following a review by an External Data Monitoring Committee, which assessed the benefit-risk profile of the drug. BELLWAVE-008 and BELLWAVE-010 were also halted as part of the broader program shutdown. Reuters reported the discontinuation followed a risk assessment by the company.
Separately in oncology news, Sellas Life Sciences reported that its galinpepimut-S maintenance therapy met the primary endpoint in the Phase 3 REGAL trial for acute myeloid leukemia. The 80-event interim analysis showed a statistically significant 41% reduction in mortality risk versus best available treatment, with a hazard ratio of 0.59 and a p-value of 0.035, extending median overall survival to 24.0 months from 14.7 months with no new safety signals. The company said it plans to consult the FDA and targets a BLA submission in the first half of 2027.
© AI-generated summary is provided by Market Flux
Sources
- Seeking AlphaIdeaya Biosciences: Staying Bullish On Darovasertib NDA Submission And More
- Business WireMerck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
- FaststocknewssMERCK $MRK DISCONTINUES PHASE 3 BELLWAVE-011, -008 AND -010 STUDIES OF NEMTABRUTINIB • BELLWAVE-011 (NCT06136559) discontinued after an EDMC review • BELLWAVE-008 and BELLWAVE-010 also discontinued
- InvestingForm 8K INTERPACE BIOSCIENCES For: 17 November
- BPharmCatalyst$SLS Galinpepimut-S (GPS) maintenance therapy met its primary endpoint in the Phase 3 REGAL trial for acute myeloid leukemia. Results showed a statistically significant 41% mortality risk reduction versus best available treatment (HR 0.59; p=0.035), extending median overall survival to 24.0 months from 14.7 months, with no new safety signals. Following these 80-event interim data, the company plans to consult the FDA ahead of a targeted H1 2027 BLA submission. $SLS $GLSI $SNTI $CMND $KYNB $DARE $AYTU $CVKD $CUE $SCLX For more biotech updates, join us on 🔗 BioPharmCatalyst 📰 Articles section
- ReutersMerck stops trials of blood cancer drug after risk assessment